William Blair analyst Matt Larew downgraded AptarGroup (ATR) to Market Perform from Outperform without a price target The company reported “mixed” ...
1d
AptarGroup outlines 35% decline in emergency medicine revenue for 2026 amid shifting pharma demand
Get key insights from AptarGroup’s Q3 2025 earnings call—injectables growth, Brazil expansion, and 2026 margin headwinds. See what’s next for ATR.
AptarGroup (ATR) reported $961.13 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 5.7%. EPS of $1.62 for the same period compares to $1.49 a year ...
AptarGroup (ATR) delivered earnings and revenue surprises of +3.18% and +0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Rakovina Therapeutics Inc. announced promising results from its AI-driven kt-5000AI drug discovery program at the AACR-NCI-EORTC International Conference. The company showcased novel ATR inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback